GoodRx (GDRX) Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares.
View GDRX analyst ratings or view top-rated stocks.

14 brokerages have issued 1 year price targets for GoodRx's shares. Their GDRX share price forecasts range from $6.50 to $12.00. On average, they anticipate the company's stock price to reach $8.44 in the next year. This suggests a possible upside of 49.9% from the stock's current price.
View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts.

GoodRx's stock was trading at $4.66 at the beginning of 2023. Since then, GDRX shares have increased by 20.8% and is now trading at $5.63.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our GDRX earnings forecast.

GoodRx Holdings, Inc. (NASDAQ:GDRX) issued its earnings results on Wednesday, August, 9th. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.01. The company earned $189.68 million during the quarter, compared to the consensus estimate of $186.90 million. GoodRx had a trailing twelve-month return on equity of 2.44% and a net margin of 1.58%.

ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include Invesco Next Gen Media and Gaming ETF (PBS), WisdomTree Growth Leaders Fund (PLAT) and Global X Telemedicine & Digital Health ETF (EDOC).IQ Chaikin U.S. Small Cap ETF (CSML).

GoodRx updated its third quarter 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $186.00 million-$190.00 million, compared to the consensus revenue estimate of $192.58 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

(GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

GoodRx trades on the NASDAQ under the ticker symbol "GDRX."

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GDRX stock can currently be purchased for approximately $5.63.

GoodRx (NASDAQ:GDRX) has a market capitalization of $2.24 billion and generates $745.09 million in revenue each year. The company earns $-32,830,000.00 in net income (profit) each year or $0.03 on an earnings per share basis.

The company employs 952 workers across the globe.

GoodRx's mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The official website for the company is www.goodrx.com. The company can be reached via phone at 855-268-2822 or via email at alex@blueshirtgroup.com.